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The accuracy of platelet count measurement is important for the diagnosis and management of 
thrombocytopenia, which is defined as platelet count <150x109/L(1), although new age- and sex-
specific reference intervals should be adopted(2). An exception is immune thrombocytopenia (ITP), 
which is diagnosed when the platelet count is lower than 100x109/L (3-5). Although the relationship 
between platelet count and the bleeding risk has never been validated in the clinical setting, 
platelet count guides treatment choice for thrombocytopenic patients who have to undergo surgical 
interventions, invasive procedures or delivery, or for prophylaxis with platelet transfusions of 
patients undergoing myeloablative chemotherapy (4-6). 
Pseudothrombocytopenia, a spuriously low platelet count caused by antibody-induced in 
vitro platelet agglutination, is observed in 0,07%-0,27% of tripotassium-ethylenediaminetetraacetic 
acid (K3EDTA)-anticoagulated blood samples (7, 8). Failure to identify pseudothrombocytopenia 
may impose the physician to request further, unnecessary and expensive diagnostic tests and 
expose patients to unnecessary, expensive and potentially dangerous treatments. We showed that 
some degree of time-dependent platelet agglutination in K3EDTA-blood also occurs in some 
patients with thrombocytopenia, leading to underestimation of their platelet count. Collection of 
blood samples in citrate-tris-pyridoxalphosphate (CPT) instead of K3EDTA attenuated the severity 
of this artefact, but did not completely prevent it (9). More recently, it was shown that the frequency 
of psudothrombocytopenia was lowest in blood samples anticoagulated with magnesium sulphate 
(MgSO4) (10, 11).  
Aims of our study were to extend our previous observations (9) by: 1) comparing platelet 
counts by hematology analyzer in blood samples collected in four different anticoagulants, 
including MgSO4, with those obtained by flow cytometry, which is the gold standard method for 
platelet counting (12); 2) evaluating the effect of time elapsed since blood sampling on platelet 
counts; 3) comparing the effects of different anticoagulants on the accuracy and stability over time 
of platelet count measurement in healthy subjects and thrombocytopenic patients. 
One-hundred patients with thrombocytopenia were enrolled in the study (M/F, 49/51, 
median age 67 years, IQR=46-76): 3 had inherited thrombocytopenia and  97 had the following 
acquired thrombocytopenias: ITP (n=42), hypersplenism-associated thrombocytopenia (n=31), 
multifactorial thrombocytopenia (n=11), gestational thrombocytopenia (n=6), clonal hematopoietic 
disease (n=4), other/unknown forms (3 patients were lost at follow-up when the diagnostic work-up 
was still ongoing) (n=6). One-hundred healthy subjects (M/F, 49/51, median age 36 years, 
IQR=25-45) were recruited among blood donors of our Hospital. 
Venous blood samples were drawn using a 21-gauge butterfly needle. Non-anticoagulated 
blood diluted 1:40 with PBS was tested for platelet count by flow cytometry (BD FACS Canto, 
Becton Dickinson) immediately after sampling, in the presence of an anti-CD41a monoclonal 
antibody (Becton Dickinson). The following anticoagulants were used to collect blood samples for 
platelet counting by COULTER® LH 750 Hematology Analyzer (Beckman Coulter,): K3EDTA 
(Sarstedt AG&Co.), Citrate-Theophylline-Adenosine-Dipyridamole (CTAD) (Becton Dickinson), 
home-made Citrate-Tris-Pyridossalphosphate (CPT, 17 mmol/L tri-sodium citrate+11.3 mmol/L 
pyridoxal 50-phosphate+24.76 mmol/L Tris) (9) and MgSO4 (Sarstedt AG&Co.). Cell counts were 
performed in each anticoagulated sample immediately after sampling (t0) and after 20 (t20), 40 
(t40), 60 (t60), 120 (t120), 180 (t180) minutes storage at room temperature. The coefficients of 
variation (CV) were 2.67% for flow cytometry and 2.52% for the hematology analyzer. 
Four categories of clinically relevant platelet counts were predefined: 100-149x109/L (very 
mild thrombocytopenia of any type except ITP, with very low bleeding risk); 50-99x109/L (any type 
of thrombocytopenia with low bleeding risk); 20-49x109/L (any type of thrombocytopenia with 
intermediate bleeding risk; need for treatment in selected patients with concomitant conditions 
increasing the bleeding risk); <20x109/L (any type of thrombocytopenia with high bleeding risk; 
need for treatment in most instances). The study was approved by the Ethics Committee of 
Ospedale San Paolo, Milano,. 
Data are shown as medians and ranges. Differences were analysed using Friedman's 
analysis of variance (ANOVA) followed by Dunn's post hoc test. Differences between frequencies 
were analysed using the Mc Nemar’s test. P values <0.05 were considered statistically significant. 
In thrombocytopenic patients, the median platelet count measured at t0 in non-
anticoagulated blood by flow cytometry was not significantly different from those measured by 
hematology analyzer in K3EDTA, CPT- and MgSO4-anticoagulated samples, but significantly 
higher than in CTAD-samples (Table1): this difference (5%) was higher than the CV of the method 
(2.7%). The agreement (Cohen's kappa, k) between flow cytometry and hematology analyzer in 
categorizing patients to the four prespecified bleeding risk categories at t0 was optimal (k=80-
100%) for all anticoagulants: k=0.88 for K3EDTA-; k=0.86 for CTAD; k=0.90 for CPT; k=0.93 for 
MgSO4. There were no statistically significant differences among median platelet counts at t0 in 
healthy subjects (Table 1). 
The median platelet counts of thrombocytopenic patients were significantly lower at t180 
than at t0 with all tested anticoagulants (Table 1). The time-dependent decrease in platelet count 
was faster with K3EDTA than with the other anticoagulants: compared with t0, a significantly lower 
platelet count was observed at t40 with K3EDTA and at t120 with the other anticoagulants (Table 
1). The mean percent reductions of median platelet counts observed ranged between 4% and 
17%, which were higher than the CV of the method (2,5%). 
Due to the observed time-dependent in vitro decrease in their platelet counts, some 
patients would have been assigned to higher bleeding risk categories at t180, compared to t0: 16 
patients (16%) considering blood samples in K3EDTA, 9 (9%) in CPT, 8 (8%) in CTAD and 5 (5%) 
in MgSO4 (Table 2): the differences between K3EDTA and CTAD (p=0.034) or MgSO4 (p=0.0045) 
were statistically significant. In contrast, only 2 patients (2%) in K3EDTA, 1 (1%) in CTAD, 4 (4%) 
in CPT and 2 (2%) in MgSO4 shifted from higher-risk to lower risk category, with no statistically 
significant differences among anticoagulants (Table 2). Compared with the CV of the method 
(2.5%), shifts from lower to higher risk categories were higher, while those from higher to lower-risk 
categories were of a similar magnitude. 
In healthy subjects, the platelet count was more stable over time: statistically significant 
decreases in platelet counts from t0 were observed at t60 and t180 in K3EDTA, at t120 and t180 in 
CTAD (table 1). The degree of reduction was always <2%. 
This is the first study comparing platelet counting by hematology analyzer in whole blood 
samples collected in four different anticoagulants to the results obtained by flow cytometry in non-
anticoagulated samples, which is the “gold standard” for platelet count determination (12). Our 
study shows that the baseline platelet counts measured by hematology analyzer agree with those 
measured by flow cytometry, both in thrombocytopenic patients and healthy controls, 
independently of the anticogulant used, with the exception of CTAD. In addition, the agreement 
with flow cytometry in assigning thrombocytopenic patients to four pre-defined bleeding risk 
categories, based on the baseline platelet count, was optimal for all tested anticoagulants. 
Our study also shows that the platelet count in anticoagulated blood samples from patients 
with different types of thrombocytopenia decreases in vitro over time when blood samples are 
stored at room temperature before testing. The decrease was observed with any anticoagulant, 
although it was more remarkable with K3EDTA. The same pattern of in vitro decrease in the 
platelet count was not observed in blood samples from healthy controls. The mechanism 
responsible for this artefact is likely the same that is responsible for pseudothrombocytopenia, 
which is caused by platelet agglutination mediated by antibodies against the platelet GPIIb-IIIa 
complex. In accordance with the results of a previous study in subjects with 
pseudothrombocytopenia (10), the time-dependent in vitro decrease in platelet count was minimal 
in blood samples anticoagulated with MgSO4. The observation that no changes in platelet count 
occurred in vitro over time in samples from healthy subjects suggests that antibodies that cause 
thrombocytopenia may also be responsible for the observed anticoagulant-dependent in vitro 
decrease in platelet count. 
The results of our study have relevant clinical implications, because therapeutic decisions 
for thrombocytopenic patients are largely based on their platelet counts. In our cohort of 
thrombocytopenic patients, the platelet count in K3EDTA, CTAD, MgSO4 and CPT samples 
significantly decreased during 180 min storage of blood samples at room temperature. Based on 
their platelet counts at t180 some patients would have been assigned to a higher bleeding risk 
category, possibly inducing physicians to start unnecessary, expensive and potentially toxic 
treatments. Although this misclassification of patients was observed with all tested anticoagulants, 
its magnitude was significantly lower with CTAD and MgSO4 than with K3EDTA. Considering that 
the time lapse occurring in everyday clinical practice between blood sampling and laboratory 
measurement of blood cell count in large hospitals could be even longer than 180 minutes, our 
findings are relevant to common clinical practice. 
Based on the results of our study, MgSO4 should be recommended for collecting blood 
samples for platelet count measurement, because it was associated with the lowest in vitro 
decrease in platelet count, in agreement with the demonstration of a very low prevalence of 
pseudothrombocytopenia in MgSO4-anticoagulated samples (10, 11, 13). However, MgSO4 does 
not completely prevent the artefact in all samples and is more expensive than K3EDTA. An easier 
and more practical suggestion would be to repeat platelet count measurements in K3EDTA-
samples immediately after blood withdrawal, before taking any therapeutic decision in patients with 
critical thrombocytopenia. 
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 Table 1 – Platelet counts and their variations over time since blood sampling in healthy subjects 
and thrombocytopenic patients: comparison of different techniques and anticoagulants for 
blood samples 
K3EDTA=tripotassium-ethylenediaminetetraacetic acid; CTAD=Citrate-Theophylline-Adenosine-
Dipyridamole; CPT=Citrate-Tris-Pyridossalphosphate; MgSO4=magnesium sulfate. 
Median values (IQR). Friedman's analysis of variance (ANOVA) followed by Dunn's post hoc test. ANOVA 
test from t0 to t180 was statistically significant for all anticoagulants. °p<0.05 vs flow cytometry a t0. 
*p<0.05 vs t0 
 
  
Time since 
blood 
sampling 
Flow 
citometry 
COULTER® LH 750 Hematology Analyzer 
No 
anticoagulant 
K3EDTA 
anticoagulant 
CTAD 
anticoagulant 
CPT 
anticoagulant 
MgSO4 
anticoagulant 
 
 A –  HEALTHY SUBJECTS (plateletsx10
9
/L) 
t0 
240 (203-292)  239 (208-288) 238 (211-292) 244 (209-292) 239 (208-290) 
t20 
 237 (206-291) 241 (209-290) 239 (211-294) 238 (207-290) 
t40 
 237 (266-285) 240 (206-288) 239 (211-293) 237 (207-285) 
t60 
 235 (207-286)* 242 (208-300) 237 (211-288) 238 (207-289) 
t120 
 237 (208-282) 237 (207-288)* 241 (210-290) 239 (208-284) 
t180 
 238 (208-289)* 234 (202-287)* 240 (215-284) 236 (208-289) 
  B – THROMBOCYTOPENIC PATIENTS (plateletsx10
9
/L) 
t0 80 (47-102) 76 (45-99)  76 (46-95)° 83 (46-100) 79 (45-97) 
t20  74 (44-96) 74 (43-96) 80 (46-97) 79 (45-95) 
t40  72 (43-95)* 75 (45-96) 74 (47-96) 76 (44-95) 
t60  68 (43-93)* 77 (47-93) 72 (46-99) 77 (42-94) 
t120  68 (43-94)* 69 (47-93)* 74 (41-95)* 76 (44-96)* 
t 180  66 (42-92)* 66 (42-91)* 69 (39-97)* 76 (41-95)* 
Table 2 – Shifts in bleeding risk categories from t0 to t180 in 100 thrombocytopenic patients, based on in 
vitro changes in platelet counts from t0 to t180, as a function of the anticoagulant for blood samples 
 Shifts to categories at higher bleeding risk 
number of shifted patients/total patients at lower risk category at t0 (%) 
Lower-risk 
category⇒ 
higher-risk 
category 
K3EDTA 
anticoagulant 
CTAD 
anticoagulant 
CPT 
anticoagulant 
MgSO4 
anticoagulant 
100-149⇒50-99  
(plt x 109/L) 
9/24 (38%) 5/21 (24%) 4/25 (16%) 3/23 (13%) 
50-99⇒20-49  
(plt x 109/L) 
5/48 (10%) 2/50 (4%) 5/47 (11%) 1/48 (2%) 
20-49⇒0-19  
(plt x 109/L) 
2/22 (9%) 1/23 (4%) 0/21 (0%) 1/23 (4%) 
Total shifts from 
lower to higher 
bleeding risk 
category at t180 
16/100 (16%) 8/100 (8%)* 9/100 (9%) 5/100 (5%)* 
 
Shifts to categories at lower bleeding risk 
number of shifted patients/total patients at higher risk category at t0 (%) 
Higher-risk 
category⇒ 
lower-risk 
category 
K3EDTA 
anticoagulant 
CTAD 
anticoagulant 
CPT 
anticoagulant 
MgSO4 
anticoagulant 
50-99 ⇒100-149 
(plt x 109/L) 
0/48 (0%) 0/50 (0%) 1/47 (2%) 2/48 (4%) 
20-49⇒50-99  
(plt x 109/L) 
1/22 (5%) 1/23 (4%) 3/21 (14%) 0/23 (0%) 
0-19⇒20-49  
(plt x 109/L) 
1/6 (17%) 0/6 (0%) 0/7 (0%) 0/6 (0%) 
Total shifts from 
higher to lower 
bleeding risk 
category at t180 
2/100 (2%) 1/100 (1%) 4/100 (4%) 2/100 (2%) 
K3EDTA=tripotassium-ethylenediaminetetraacetic acid; CTAD=Citrate-Theophylline-Adenosine-
Dipyridamole; CPT=Citrate-Tris-Pyridossalphosphate; MgSO4=magnesium sulfate 
Data were analyzed using the Mc Nemar’s test. *p<0.05 vs K3EDTA 
 
